BCL2 and B-cell chronic lymphocytic leukemia: Nowadays, a Bcl-2-selective BH3-mimetic compound, ABT-199 (venetoclax) established by AbbVie is currently implemented to treat 17p-deleted CLL patients [10] without affecting platelet survival [11–13].